Omada Health, Inc. (NASDAQ:OMDA - Get Free Report) CAO Craig Gracey sold 644 shares of the firm's stock in a transaction on Wednesday, September 9th. The shares were sold at an average price of $21.73, for a total value of $13,994.12. Following the sale, the chief accounting officer directly owned 14,412 shares in the company, valued at approximately $313,172.76. This trade represents a 4.28% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Craig Gracey also recently made the following trade(s):
- On Monday, August 10th, Craig Gracey sold 1,042 shares of Omada Health stock. The stock was sold at an average price of $25.00, for a total value of $26,050.00.
- On Wednesday, July 1st, Craig Gracey sold 637 shares of Omada Health stock. The shares were sold at an average price of $23.00, for a total value of $14,651.00.
- On Tuesday, June 30th, Craig Gracey sold 405 shares of Omada Health stock. The shares were sold at an average price of $22.00, for a total value of $8,910.00.
- On Monday, June 29th, Craig Gracey sold 2,083 shares of Omada Health stock. The stock was sold at an average price of $21.00, for a total value of $43,743.00.
- On Friday, June 26th, Craig Gracey sold 2,084 shares of Omada Health stock. The shares were sold at an average price of $20.00, for a total value of $41,680.00.
- On Wednesday, June 24th, Craig Gracey sold 2,083 shares of Omada Health stock. The stock was sold at an average price of $19.01, for a total transaction of $39,597.83.
- On Monday, June 22nd, Craig Gracey sold 2,083 shares of Omada Health stock. The shares were sold at an average price of $18.00, for a total transaction of $37,494.00.
Omada Health Stock Down 8.6%
Shares of OMDA stock traded down $1.84 during trading hours on Friday, hitting $19.66. 1,647,637 shares of the company's stock traded hands, compared to its average volume of 1,252,016. The stock has a market cap of $1.20 billion, a PE ratio of 393.20 and a beta of 1.86. The stock's 50 day simple moving average is $22.68 and its 200 day simple moving average is $17.91. Omada Health, Inc. has a 12 month low of $10.28 and a 12 month high of $26.92.
Omada Health (NASDAQ:OMDA - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported $0.08 earnings per share for the quarter, topping the consensus estimate of ($0.02) by $0.10. The company had revenue of $87.83 million for the quarter, compared to analysts' expectations of $80.93 million. Omada Health had a net margin of 1.39% and a return on equity of 2.60%. As a group, equities research analysts expect that Omada Health, Inc. will post 0.09 EPS for the current fiscal year.
Hedge Funds Weigh In On Omada Health
Several institutional investors have recently added to or reduced their stakes in OMDA. Walleye Capital LLC acquired a new position in Omada Health during the second quarter worth $11,648,000. AlpInvest Partners B.V. acquired a new position in shares of Omada Health during the second quarter valued at about $1,182,000. GSA Capital Partners LLP bought a new stake in shares of Omada Health during the second quarter worth about $1,289,000. BlackRock Inc. bought a new stake in shares of Omada Health during the second quarter worth about $48,775,000. Finally, a16z Perennial Management L.P. acquired a new stake in shares of Omada Health in the 4th quarter worth about $2,480,000.
Analyst Ratings Changes
Several equities research analysts have recently weighed in on the company. Robert W. Baird increased their price target on Omada Health from $15.00 to $25.00 and gave the company a "neutral" rating in a research note on Wednesday, August 12th. Wall Street Zen raised Omada Health from a "hold" rating to a "buy" rating in a research note on Saturday, August 8th. BMO Capital Markets reiterated an "outperform" rating and issued a $24.00 target price on shares of Omada Health in a report on Friday, August 7th. Citizens Jmp increased their target price on shares of Omada Health from $27.00 to $32.00 and gave the company a "market outperform" rating in a research report on Friday, August 14th. Finally, Citigroup restated an "outperform" rating on shares of Omada Health in a report on Friday, August 14th. Eleven investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $26.67.
View Our Latest Stock Analysis on Omada Health
Key Omada Health News
Here are the key news stories impacting Omada Health this week:
- Positive Sentiment: Analyst support remains strong: BTIG Research reaffirmed its “buy” rating and set a $35 price target, while Needham & Company also maintained a “buy” rating with a $28 target. These targets imply significant potential upside and reinforce confidence in Omada’s growth outlook.
- Positive Sentiment: Investor Day could provide new growth targets: Omada held its inaugural Investor Day and planned to present updated long-term financial targets. More ambitious revenue, profitability, or membership goals could improve investor confidence if management’s outlook exceeds current expectations. Omada Health to Present Updated Long-Term Financial Targets at Inaugural Investor Day
- Neutral Sentiment: Investor Day transcript available: The transcript may offer additional detail on Omada’s strategy and financial targets, but the supplied report does not identify specific changes that would immediately alter earnings expectations. Omada Health Analyst/Investor Day Transcript
- Negative Sentiment: Chief accounting officer sold shares: CAO Craig Gracey sold 644 shares for approximately $14,000, reducing his direct ownership by 4.28%. The relatively small transaction is not necessarily a sign of deteriorating fundamentals, but insider selling can create short-term negative sentiment. SEC Insider Transaction Filing
Omada Health Company Profile
(
Get Free Report)
Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company's platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.
In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Omada Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Omada Health wasn't on the list.
While Omada Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.